Delaware Education Research and Development Center, University of Delaware School of Education, Newark, USA.
Am J Geriatr Psychiatry. 2010 Dec;18(12):1124-32. doi: 10.1097/JGP.0b013e3181dd1c3b.
Early and progressive cognitive impairments of patients with Alzheimer disease (AD) hinder their capacity to provide informed consent. Unfortunately, the limited research on techniques to improve capacity has shown mixed results. Therefore, the authors tested whether a memory and organizational aid improves the performance of patients with AD on measures of capacity and competency to give informed consent.
DESIGN, SETTING, AND PARTICIPANTS: Patients with AD randomly assigned to standard consent or standard plus a memory and organizational aid.
Memory and organizational aid summarized the content of information mandated under the informed consent disclosure requirements of the Common Rule at a sixth grade reading level.
Three psychiatrists without access to patient data independently reviewed MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR) interview transcripts to judge whether the patient was capable of providing informed consent. The agreement of at least two of the three experts defined a participant as capable of providing informed consent. Secondary outcomes are MacCAT-CR measures of understanding, appreciation and reasoning, and comparison with cognitively normal older adult norms.
AD intervention and control groups were similar in terms of age, education, and cognitive status. The intervention group was more likely to be judged competent than control group and had higher scores on MacCAT-CR measure of understanding. The intervention had no effect on the measures of appreciation or reasoning.
A consent process that addresses the deficits in memory and attention of a patient with AD can improve capacity to give informed consent for early phase AD research. The results also validate the MacCAT-CR as an instrument to measure capacity, especially the understanding subscale.
ClinicalTrials.Gov#NCT00105612, http://clinicaltrials.gov/show/NCT00105612.
阿尔茨海默病(AD)患者的早期和进行性认知障碍阻碍了他们提供知情同意的能力。不幸的是,关于提高能力的技术的有限研究结果喜忧参半。因此,作者测试了记忆和组织辅助工具是否可以提高 AD 患者在能力和同意告知的能力方面的表现。
设计、地点和参与者:随机分配 AD 患者接受标准同意或标准加记忆和组织辅助。
记忆和组织辅助工具以六年级阅读水平总结了《普通规则》规定的知情同意披露要求下的信息内容。
三位没有访问患者数据的精神科医生独立审查 MacArthur 临床研究能力评估工具(MacCAT-CR)访谈记录,以判断患者是否有能力提供知情同意。至少两位专家的意见一致定义为有能力提供知情同意的参与者。次要结果是 MacCAT-CR 对理解、欣赏和推理的测量,以及与认知正常的老年成年人的标准进行比较。
AD 干预组和对照组在年龄、教育和认知状况方面相似。干预组比对照组更有可能被判断为有能力,并且在 MacCAT-CR 理解测量上的得分更高。干预对欣赏或推理的测量没有影响。
针对 AD 患者记忆和注意力缺陷的同意过程可以提高早期 AD 研究的知情同意能力。结果还验证了 MacCAT-CR 作为衡量能力的工具,特别是理解子量表。
ClinicalTrials.Gov#NCT00105612,http://clinicaltrials.gov/show/NCT00105612。